{"nctId":"NCT02981446","briefTitle":"A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT","startDateStruct":{"date":"2017-01","type":"ACTUAL"},"conditions":["Open Angle Glaucoma or Ocular Hypertension"],"count":370,"armGroups":[{"label":"DE-117 ophthalmic solution","type":"EXPERIMENTAL","interventionNames":["Drug: DE-117"]},{"label":"Latanoprost ophthalmic solution 0.005%","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Latanoprost ophthalmic solution"]}],"interventions":[{"name":"DE-117","otherNames":[]},{"name":"Latanoprost ophthalmic solution","otherNames":["Xalatan"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with open angle glaucoma or ocular hypertension in both eyes\n\nExclusion Criteria:\n\n* Patients at risk of progression of visual field loss\n* Patients with severe visual field defect\n* Patients with any diseases that preclude participation in this study for safety reasons","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Diurnal IOP at Month 3","description":"The IOP (mmHg) measured in the study eye (identified at Day 1 \\[baseline\\]) was the efficacy measure for this study. The IOP was measured using a calibrated Goldmann applanation tonometer preferably by the same Investigator (operator) and the same authorized study staff (recorder) during the study for each subject.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":"0.25"},{"groupId":"OG001","value":"16.8","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"IOP at 9 Timepoints (First Key Secondary Efficacy Endpoint)","description":"The IOP (mmHg) measured in the study eye (identified at Day 1 \\[baseline\\]) was the efficacy measure for this study. The IOP was measured using a calibrated Goldmann applanation tonometer preferably by the same Investigator (operator) and the same authorized study staff (recorder) during the study for each subject.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","spread":"0.28"},{"groupId":"OG001","value":"18.8","spread":"0.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":"0.28"},{"groupId":"OG001","value":"18.4","spread":"0.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":"0.28"},{"groupId":"OG001","value":"18.3","spread":"0.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":"0.26"},{"groupId":"OG001","value":"17.4","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":"0.27"},{"groupId":"OG001","value":"17.2","spread":"0.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":"0.26"},{"groupId":"OG001","value":"17.1","spread":"0.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":"0.27"},{"groupId":"OG001","value":"17.0","spread":"0.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","spread":"0.25"},{"groupId":"OG001","value":"16.7","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","spread":"0.26"},{"groupId":"OG001","value":"16.7","spread":"0.27"}]}]}]},{"type":"SECONDARY","title":"Mean Diurnal IOP at Week 1 (Second Key Secondary Endpoint)","description":"The IOP (mmHg) measured in the study eye (identified at Day 1 \\[baseline\\]) was the efficacy measure for this study. The IOP was measured using a calibrated Goldmann applanation tonometer preferably by the same Investigator (operator) and the same authorized study staff (recorder) during the study for each subject.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":"0.26"},{"groupId":"OG001","value":"18.5","spread":"0.27"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":185},"commonTop":["Conjunctival hyperaemia","Dry eye","Photophobia","Eye pain","Corneal thickening"]}}}